Navigation Links
Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
Date:9/3/2014

ROCKVILLE, Md., Sept. 3, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is scheduled to present at 10:25 a.m. (Eastern Time) on Tuesday, September 9, 2014 at the New York Palace Hotel in New York City.

A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the internet at http://wsw.com/webcast/rrshq24/syn. After the presentation, a replay will be archived and accessible for 30 days at the same website.

Mr. Riley, as well as Synthetic Biologics' CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with investors and analysts who are registered to attend the conference. If you are an institutional investor, and would like to attend the Company's presentation, please register for the Rodman & Renshaw conference using the following link www.rodm.com. Once your registration is confirmed, you will be prompted to log into the conference website and may request a one-on-one meeting with the Company.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique
2. Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections
3. Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
4. Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
5. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
6. Synthetic Biologics to Report Second Quarter 2014 Financial Results
7. Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
8. Global Synthetic Biology Market 2014-2018
9. Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference
10. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic
11. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... by one of the nation’s premier cannabis technology and application experts, Chip Baker. ... CEO of Cultivate Colorado. Over the past 30 years, Chip Baker other industry ...
(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
(Date:12/4/2016)... BELLINGHAM, Washington, USA (PRWEB) , ... December 02, ... ... the role of innovative U.S.-owned and -operated small businesses in federally funded research ... SPIE, the international society for optics and photonics . , As part ...
Breaking Biology Technology:
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/9/2016)... innovation leader in attendance control systems is proud to announce the introduction of fingerprint ... sure the right employees are actually signing in, and to even control the opening ... ... ... Photo ...
Breaking Biology News(10 mins):